News

Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 Patent

STOUGHTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today…

1 year ago

DLH to Announce Fiscal 2023 Fourth Quarter Financial Results

ATLANTA, Nov. 27, 2023 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading healthcare and…

1 year ago

Philips improves workflow and efficiency with next generation ultrasound systems EPIQ Elite and Affiniti at #RSNA23

Clinician using next generation EPIQ Elite VM10 with a patient Remote collaboration ultrasound EPIQ Elite VM10 November 27, 2023 Improved…

1 year ago

Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams

Pace of Nociscan orders accelerated 2.5x for the last 250 scans compared to the first 250 scans Further acceleration of…

1 year ago

Spectral AI Appoints Erich Spangenberg as Chairman of the Executive Committee of the Board of Directors

DALLAS, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence…

1 year ago

iCAD’s ProFound AI Can Predict 1-2 Year Risk for Breast Cancer and Reveal Insights for Heart Disease

New research presented at Radiological Society of North America annual meeting confirms ability of ProFound Breast Health Suite to predict…

1 year ago

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

Mr. Schachle Brings Over 30 Years of Experience in Biotech and Pharma with Expertise Across Multiple Functional Areas Including Corporate…

1 year ago

Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023

BOTHELL, Wash., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James…

1 year ago

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today…

1 year ago

Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus

Oral brepocitinib failed to meet its primary endpoint of Systemic Lupus Erythematosus Responder Index (SRI-4) change of 4 at Week…

1 year ago